Some systematic reviews have summarized the currently known and relevant NSCLC genetic markers (e.g., EGFR, EML4/ALK mutations), and other markers for which there is insufficient evidence for use in clinical decision-making (e.g., K-RAS, ERCC1, BRCA, Beta tubulin III, RRM1, TP-53 mutations) [70–72]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.